Epistemic AI Analysis Reveals Strategic Business Decisions as the Leading Driver of Phase 3 Clinical Trial TerminationsNew study in Nature Reviews Drug Discovery shows late-stage failure rates have doubled since 2013, shifting from scientific to strategic catalysts.
